PFE | Recession Proof Stock | Fundamental and Technical analysis

PFE

Pfizer Inc. (PFE) is a leading pharmaceutical company with a diverse portfolio of drugs and products, including vaccines, oncology, and rare disease treatments. The successful rollout of COVID-19 vaccines has been a significant driver of Pfizer's revenue growth, with revenue increasing from 41 billion in 2020 to 81 billion in 2021 and $100 billion in 2022.

Historically, healthcare demand has been relatively stable during economic downturns, as consumers prioritize their health even in times of financial hardship. While the COVID-19 pandemic has caused unprecedented disruption in the healthcare industry and the broader economy, Pfizer's strong financial position and focus on critical healthcare products and services position the company well for long-term success.

Based on my short-term technical analysis, I have a bearish target price of TP1: 37 and TP2: $34.5 and a bullish target price of TP1: TASECTORBALANCE and TP2: $46.50. It's important to consider both technical and fundamental factors, as well as the broader economic and industry-specific trends when making investment decisions.

Overall, Pfizer's strong revenue growth, diverse portfolio of products, and focus on innovation and development suggest a strong outlook for the company. While the ongoing impacts of the COVID-19 pandemic and related public health measures should be monitored, Pfizer's financial strength and history of innovation position the company well for long-term success in the healthcare industry.

Trade closed: target reached:

bearish target hit